Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Recently, 3-drug (ECX) and 2-drug (CX) combination chemotherapy involving capecitabine showed promising results in randomized clinical trials for advanced gastric cancer (AGC). The objective of the study is to evaluate the safety and activity of ECX and CX combination chemotherapy given as first-line therapy for AGC.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Capecitabine; Cisplatin; Epirubicin

Criteria

Inclusion Criteria:

• Aged 75 years or less

• Adenocarcinoma of stomach

• Advanced, metastatic, or recurrent

• No prio chemotherapy for advanced disease

• Adequate performance status

• Adequate major organ functions

Exclusion Criteria:

• Severe comorbid illness or active infections

• Pregnancy or lactating women

• GI obstruction or malabsorption syndrome